Is Cybin Inc. (CYBN) a Buy, Sell, or Hold?
AMEX : CYBN
Cybin Inc.
$8.28 USD
$0.1 (1.22%)
- Volume
- 716.53K
- Average Volume
- 874.38K
- Market Capitalization
- $413.02M
- P/E Ratio
- -2.26
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $10.72
- Year Low
- $4.81
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.58
| Source | Headline |
|---|---|
|
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could... proactiveinvestors.com - 2026-07-15 11:34:00 |
|
CleanSpark shares surge after company secures $6.6B data center lease agreement
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center... proactiveinvestors.com - 2026-07-14 07:53:00 |
|
Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium... proactiveinvestors.com - 2026-07-14 07:20:00 |
|
Cybin: A Speculative Bet On Their Pivotal Depression Readout
Cybin operates as Helus Pharma, which is a clinical-stage biotech built around deuterated serotonergic therapies for depression and anxiety. I believe their main value driver is HLP003, which will report in Q4 2026 its Phase 3 APPROACH readout. HELP also recently raised funds in June 2026, and they don't have financial debt. So, they should have enough resources to reach this important milestone later this year. seekingalpha.com - 2026-06-27 10:40:00 |
|
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the feeds.newsfilecorp.com - 2026-05-13 08:00:00 |
|
Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)
I am upgrading Cybin Inc. to Buy, driven by recent regulatory and clinical tailwinds that favor its lead candidate, HLP003. HELP is positioned to benefit from expedited FDA pathways and increased institutional support, particularly for major depressive disorder and PTSD indications. The market undervalues HELP, trading near cash value with a 0.84x forward price-to-book and an $85M EV versus $195M in cash. seekingalpha.com - 2026-04-21 15:51:32 |
|
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,... proactiveinvestors.com - 2026-04-21 09:48:00 |
|
Psychedelics stocks rise after Trump order expands research, access pathways
Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating... proactiveinvestors.com - 2026-04-20 05:56:00 |
